{"id":"NCT01423084","sponsor":"Novartis","briefTitle":"Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years","officialTitle":"A Phase 3, Randomized, Comparative, Multicenter Observer-Blind Study Evaluating the Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-08","primaryCompletion":"2011-12","completion":"2011-12","firstPosted":"2011-08-25","resultsPosted":"2015-02-20","lastUpdate":"2015-02-20"},"enrollment":344,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Meningococcal Disease","Meningococcal Meningitis"],"interventions":[{"type":"BIOLOGICAL","name":"Serogroup B meningococcal vaccine","otherNames":[]}],"arms":[{"label":"MenB Lot 1","type":"EXPERIMENTAL"},{"label":"MenB Lot 2","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective of this study is to demonstrate the equivalence of rMenB+OMV NZ lot 1 to rMenB+OMV NZ lot 2 when administered to adolescents, as measured by human serum bactericidal activity (hSBA) geometric mean titers (GMTs) against 3 N. meningitidis serogroup B reference strains (H44/76, 5/99, and NZ98/254) and as measured by ELISA geometric mean concentrations (GMCs) against vaccine antigen 287-953, approximately 30 days after a primary vaccination course of two doses administered one month apart.","primaryOutcome":{"measure":"Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) Against 3 Neisseria.Meningitidis (N. Meningitidis) Serogroup B Reference Strains.","timeFrame":"One month after the second vaccination (day 61)","effectByArm":[{"arm":"4CMenB_Rosia","deltaMin":111,"sd":null},{"arm":"4CMenB_Siena","deltaMin":111,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"11 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":10},"locations":{"siteCount":13,"countries":["Australia","Canada"]},"refs":{"pmids":["26232542"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":169},"commonTop":["injection site pain","injection site erythema","myalgia","Headache","Fatigue"]}}